VIA
MAZE

Virtus Investment Advisers’s Maze Therapeutics MAZE Stock Holding History

Virtus Investment Advisers’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$406K Buy
13,605
+6,589
+94% +$173K 0.09% 272
2026
Q1 		$209K Buy
7,016
+170
+2% +$7.5K 0.06% 337
2025
Q4 		$284K Sell
6,846
-1,551
-18% -$53.3K 0.08% 266
2025
Q3 		$218K Buy
8,397
+1,457
+21% +$24.6K 0.06% 253
2025
Q2 		$85.2K Buy
+6,940
New +$72.2K 0.03% 401

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Virtus Investment Advisers's MAZE Position: Q2 2026 in Review

Virtus Investment Advisers increased its Maze Therapeutics (MAZE) stake by 94% in Q2 2026, buying an estimated $173K and bringing the position to 13,605 shares worth $406K. The position accounts for 0.09% of the portfolio, ranked #272.

Virtus Investment Advisers first reported a position in MAZE in Q2 2025 and has held it in 5 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Virtus Investment Advisers held 13,605 shares of Maze Therapeutics worth $406K as of Q2 2026.
  • Virtus Investment Advisers bought 6,589 Maze Therapeutics shares in Q2 2026, an estimated $173K.
  • Maze Therapeutics made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #272 holding.
  • Virtus Investment Advisers first reported a position in Maze Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.